--- title: "Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a \"Market Misread\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/293251564.md" description: "Tempus AI (TEM) stock dropped 8% following the announcement of a $1.7 billion all-stock acquisition of Personalis, driven by investor dilution concerns. However, Needham analyst Ryan Macdonald maintains a Buy rating with a $75 price target, calling the selloff a 'market misread.' He argues the deal strategically enhances Tempus' position in the minimal residual disease (MRD) testing market and boosts its data-driven cancer care platform, offering long-term growth potential despite near-term volatility." datetime: "2026-07-20T20:18:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293251564.md) - [en](https://longbridge.com/en/news/293251564.md) - [zh-HK](https://longbridge.com/zh-HK/news/293251564.md) generator: "portal-rs" --- # Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a "Market Misread" Tempus AI (TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis (PSNL) in an all-stock deal valued at $1.7 billion. The move caused a sharp reaction from investors due to dilution concerns, but Needham analyst Ryan Macdonald said the market is reading it wrong. He reiterated his Buy rating and $75 price target, saying the selloff ignores the real strategic value Personalis adds to Tempus' long-term growth plan. ### Claim 55% Off TipRanks TEMT: an alternative to margin or options on TEM Personalis adds MRD and genomic tools that fit directly into Tempus' existing platform. MRD testing is becoming a key part of cancer care, helping doctors spot tiny traces of cancer that remain after treatment. ## **Strengthening Tempus' Position in MRD and Data‑Driven Cancer Care** In Macdonald's view, the deal boosts Tempus' position in the fast‑growing minimal residual disease (MRD) testing market, which is worth over $20 billion but still has less than 10% adoption. The analyst said Tempus' commercial reach should help drive higher testing volumes across Personalis' tools, and tighter data integration could add real upside to Tempus' Insights business. The deal structure also gives Tempus flexibility. While the headline value is $1.7 billion, Tempus already owns part of Personalis, bringing the net cost closer to $1.5 billion. The company also has the option to fund up to half of the transaction in cash rather than stock. However, Macdonald said the long‑term payoff could outweigh the near‑term pressure, especially as Tempus expands its reach in cancer testing and data‑driven precision medicine. Macdonald also pointed out that tighter data integration could lift Tempus' Insights business, which uses clinical and molecular data to support drug development and research. Personalis' datasets could deepen Tempus' analytics tools and raise the value of its partnerships with biopharma companies. Finally, the analyst said the selloff creates an opportunity for investors who believe in the combined company's growth potential. ## **Is Tempus AI a Good Stock to Buy?** Overall, Tempus AI has a Moderate Buy consensus rating on TipRanks, based on eight Buys and seven Hold ratings. The average TEM price target of $437.79 implies 35.8% upside potential from current levels. ### Related Stocks - [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md) - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md) ## Related News & Research - [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md) - [Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock](https://longbridge.com/en/news/296562025.md) - [Tempus AI director Nadja West disposes of 3,000 common shares worth $161,700](https://longbridge.com/en/news/296265854.md) - [Tempus AI CFO James William Rogers disposes of USD 2.7 million in common shares](https://longbridge.com/en/news/296551053.md) - [3 arguments for and against AI watermarks](https://longbridge.com/en/news/296205500.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**